Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 20, Issue 2, Pages 65-66Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41571-022-00710-5
Keywords
-
Categories
Ask authors/readers for more resources
The first phase III trial of perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma showed promising results, leading to regulatory approvals. However, subsequent trials did not demonstrate similar benefits, and the unique design of each trial might explain some of the patterns identified.
The first phase III trial to test perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma yielded highly promising results, leading to regulatory approvals of adjuvant pembrolizumab. However, subsequent phase III trials, including the IMmotion010 trial of adjuvant atezolizumab, did not demonstrate similar benefits. Although molecular biomarkers are urgently needed to better delineate responder subgroups, the unique design of each trial might partially explain some of the patterns identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available